[1] Tan WJ, Zhao X, Ma XJ, Wang WL, Niu PH, Xu WB, et al. Notes from the field: a novel coronavirus genome identified in a cluster of pneumonia cases-Wuhan, China 2019-2020. China CDC Wkly 2020;2(4):61 − 2. http://dx.doi.org/10.46234/ccdcw2020.017CrossRef
[2] World Health Organization. WHO Director-General’s opening remarks at 148th session of the Executive Board. https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board. [2021-1-29].https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-148th-session-of-the-executive-board
[3] Johnson & Johnson. Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its phase 3 ENSEMBLE trial. https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial. [2021-1-29].https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
[4] Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial. https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3. [2021-1-29].https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3